Zevra Therapeutics (NASDAQ:ZVRA) Given New $21.00 Price Target at Roth Mkm

Zevra Therapeutics (NASDAQ:ZVRA) had its target price boosted by Roth Mkm from $19.00 to $21.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts also recently weighed in on the company. Canaccord Genuity Group cut their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a buy rating on the stock in a report on Wednesday, September 18th. Cantor Fitzgerald reissued an overweight rating on shares of Zevra Therapeutics in a research note on Wednesday, August 14th. William Blair upgraded Zevra Therapeutics to a strong-buy rating in a report on Friday, August 30th. JMP Securities started coverage on shares of Zevra Therapeutics in a report on Tuesday. They issued an outperform rating and a $17.00 price objective for the company. Finally, HC Wainwright lifted their target price on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the stock a buy rating in a research report on Friday, September 20th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Buy and a consensus target price of $21.00.

Zevra Therapeutics Stock Down 5.3 %

ZVRA stock opened at $6.92 on Tuesday. The firm has a 50-day moving average price of $7.16 and a 200-day moving average price of $5.76. Zevra Therapeutics has a 12 month low of $3.89 and a 12 month high of $8.95. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80. The stock has a market capitalization of $364.13 million, a P/E ratio of -5.13 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. The company had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. During the same period in the previous year, the company earned ($0.15) EPS. As a group, equities research analysts anticipate that Zevra Therapeutics will post -1.59 EPS for the current fiscal year.

Insider Activity

In other news, Director John B. Bode purchased 10,000 shares of the stock in a transaction on Friday, July 12th. The stock was purchased at an average price of $5.87 per share, for a total transaction of $58,700.00. Following the acquisition, the director now owns 30,000 shares in the company, valued at $176,100. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders purchased 22,000 shares of company stock valued at $140,340. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Zevra Therapeutics

Institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD bought a new position in shares of Zevra Therapeutics in the 1st quarter worth about $64,000. The Manufacturers Life Insurance Company grew its stake in Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares during the period. Focus Financial Network Inc. ADV acquired a new stake in Zevra Therapeutics during the fourth quarter worth approximately $141,000. Virtu Financial LLC bought a new stake in Zevra Therapeutics in the fourth quarter worth approximately $177,000. Finally, Jacobs Levy Equity Management Inc. lifted its stake in Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after buying an additional 17,557 shares during the period. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.